Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43927499" target="_blank" >RIV/00064173:_____/24:43927499 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10483724 RIV/00216208:11120/24:43927499 RIV/00216208:11140/24:10483724 RIV/61989592:15110/24:73625811 and 3 more
Result on the web
<a href="https://doi.org/10.1007/s12325-024-02952-4" target="_blank" >https://doi.org/10.1007/s12325-024-02952-4</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/s12325-024-02952-4" target="_blank" >10.1007/s12325-024-02952-4</a>
Alternative languages
Result language
angličtina
Original language name
Real-World Data on Brodalumab Treatment in Patients with Moderate-to-Severe Plaque Psoriasis: An Observational Study from the Czech Republic BIOREP Registry
Original language description
INTRODUCTION: The aim of this observational, multicenter study was to assess the real-world use of brodalumab for the treatment of moderate-to-severe plaque psoriasis in patients in the Czech Republic, using data from the BIOREP registry. METHODS: The study included 273 patients aged >= 18 years with moderate-to-severe psoriasis who received brodalumab. Endpoints were drug survival (time from treatment initiation to discontinuation), effectiveness [Psoriasis Area and Severity Index (PASI)], and health-related quality-of-life [Dermatology Life Quality Index (DLQI)]. RESULTS: Predicted drug survival probability was 92.4% [95% confidence interval (CI): 89.1, 95.7%] at 6 months and 84.2% (95% CI 79.5, 89.1%) at 12 months; this was maintained at 24 months [80.4% (95% CI 74.5, 86.8%)]. Younger age, higher body mass index, and no previous biologic treatment were significantly associated with longer drug survival. Absolute PASI <= 3 after 3 months was achieved by 89.8% of patients; 92.4%, 77.8%, and 59.1% reached PASI 75, PASI 90, and PASI 100, respectively. After 12 months, 96.5% of 141 patients had an absolute PASI <= 3. The proportion of patients achieving DLQI 0/1 was 87.3% at 12 months. CONCLUSION: This study demonstrated high and sustained drug survival with high rates of skin clearance and improved quality of life in patients with relatively severe disease treated with brodalumab. Improvements were observed as early as 3 months post-treatment initiation and were sustained for up to 24 months in a real-life setting.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30216 - Dermatology and venereal diseases
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Advances in Therapy
ISSN
0741-238X
e-ISSN
1865-8652
Volume of the periodical
41
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
21
Pages from-to
3951-3971
UT code for WoS article
001303260000002
EID of the result in the Scopus database
2-s2.0-85202601589